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Theformationofreactiveoxygenspecies(ROS)isaresultofincompletereductionofmolecularoxygenduringcellularmetabolism.
AlthoughROShasbeenshowntoactassignalingmolecules,itisknownthatthesereactivemoleculescanactasprooxidantscausing
damage to DNA, proteins, and lipids, which over time can lead to disease propagation and ultimately cell death. Thus, restoring
the protective antioxidant capacity of the cell has become an important target in therapeutic intervention. In addition, a clearer
understanding of the disease stage and molecular events that contribute to ROS generation during tumor promotion can lead to
novel approaches to enhance target speciﬁcity in cancer progression. This paper will focus on not only the traditional routes of
ROS generation, but also on new mechanisms via the tumor suppressor p53 and the interaction between p53 and MnSOD, the
primary antioxidant enzyme in mitochondria. In addition, the potential consequences of the p53-MnSOD interaction have also
been discussed. Lastly, we have highlighted clinical implications of targeting the p53-MnSOD interaction and discussed recent
therapeutic mechanisms utilized to modulate both p53 and MnSOD as a method of tumor suppression.
1.Introduction
Oxidative stress has been deﬁned as the cellular imbalance
of prooxidants versus antioxidants that overwhelms the cell’s
capacity to scavenge the oxidative load and contributes to
the pathogenesis of various diseases. Reactive oxygen species
(ROS) are free radicals derived from molecular oxygen that
play a key role in promoting oxidative stress. These radicals
result from the incomplete reduction of oxygen mainly dur-
ing mitochondrial respiration. There are several products
of oxygen metabolism, both nonradicals and radicals that
f o r mR O Ss u c ha sh y d r o g e np e r o x i d e( H 2O2)a n ds u p e r -
oxide anions (O2
.−). Contributors of ROS can modify the
intracellular redox status through unfavorable interactions
with endogenous regulators of oxidative stress. Superoxide
radicals can interact with mitochondrial nitric oxide to form
peroxynitrite which can alter antioxidant enzymes such as
aconitase and the mitochondrial complexes of the electron
transport chain [1]. On the other hand, the presence of
oxidative stress can alter normal cellular homeostasis by
modifying proteins involved in DNA repair; activating signal
transduction pathways involved in cell survival and inﬂam-
mation; as well as, inducing cellular apoptotic pathways that
are detrimental to the cell. For many years, scientists have
tried to combat free radical generation and superoxide pro-
duction through the utilization of the exogenous antioxidant
supplementation, such as ascorbate, vitamin E, as well as
linoleic acid. However, many of these trials have failed show-
ing no signiﬁcant decrease in cancer incidence, death, or
majorcardiovascularevents[2].Herein,wewillfocusonsev-
eral novel signaling pathways aﬀecting ROS generation, such
asp53signalingandtheinteractionbetweenp53andmanga-
nese superoxide dismutase (MnSOD) and how to potentially
target these pathways for cancer therapy.
2. OxidativeStress
Oxidative stress has been repeatedly shown to contribute
to the progression of multiple diseases, such as cancer [3],
diabetes [4], ulcerative colitis [5], cardiovascular disease [6],2 Journal of Signal Transduction
pulmonary disease [7]a sw e l la sn e u r o d e g e n e r a t i v ed i s e a s e s
[8]. Nevertheless, the biological signiﬁcance of oxidative
stress can be beneﬁcial or detrimental depending on certain
parameters such as concentration, duration of action, cell
type exposed, the type of free radicals and reactive metabo-
lites involved, and the activities of the associated signal
transduction pathways.
The mitochondrial electron transport chain remains
to be one of the main sources of intracellular oxidative
stress [9]. During mitochondrial respiration, electrons ﬂow
through four integral membrane protein complexes to ﬁ-
nally reduce molecular oxygen to water. However, approx-
imately 1-2% of molecular oxygen undergoes incomplete
reduction, resulting in the formation of superoxide anions
and mitochondria-mediated ROS generation [10]. Though
mainly produced from mitochondrial respiration, superox-
ide anions can be detoxiﬁed via endogenous antioxidant
enzymessuchasmanganesesuperoxidedismutase(MnSOD)
to hydrogen peroxide, which is further converted to water
via the enzymatic actions of various antioxidant enzymes
including glutathione reductases, peroxiredoxins, glutathio-
ne transferases, as well as catalase which all function in the
removal of hydrogen peroxide.
Nevertheless, it is common for cells in response to stress
to enhance ROS generation. Oxidoreductases are enzymes
that are often activated during the cellular stress response
andcatalyzethetransferofelectronsfromtheelectrondonor
(reductant)totheelectronacceptor(oxidant)[11]withasso-
ciated formation of superoxide anions and ROS as byprod-
ucts. There are several enzymes that act as oxidoreductases
and contribute to intracellular ROS generation, such as cy-
clooxygenase [12], lipoxygenase [12, 13], cytochrome P450
enzymes [14], nitric-oxide synthase [15], xanthine oxidase
[16], and mitochondrial NADH: ubiquinone oxidoreductase
(complexI)[17].NAPDHoxidasesoftheNoxfamilyarealso
oxidoreductasesthatproducesuperoxideanionsasaprimary
product and one of the key sources of intracellular ROS
formation. NADPH oxidases (Nox) are endogenous enzy-
matic heterogenic complexes that reduce molecular oxygen
tosuperoxide,inconjunctionwithNADPHoxidation,which
c a nb ec o n v e r t e dt ov a r i o u sR O S .N o xc a nb ea c t i v a t e db ya
myriadofcellularstressstimulisuchasheavymetals[18,19],
organic solvents [20], UV and ionizing irradiation [21, 22].
Once the cellular stress response is initiated two cytosolic
regulatory units of Nox, p47phox,p 6 7 phox, and the small
G protein Rac translocate to the membrane and associate
with cytochrome b558 (consisting of two subunits gp91phox
(Nox2)andp22phox),whichactsasacentraldockingsitefor
complex formation [23]. Emerging evidence has linked Nox
enzymes to oxidative stress that may contribute to disease
progression[11,17,24,25].TheradicalsgeneratedfromNox
activation are capable of modulating various redox-sensitive
signaling pathways involved in the activation of mitogen-
activated protein kinases (MAPKs) and transcription factors
(NF-κB) [26–28] causing regulation of Nox activation to be
complex.
Oxidative stress can be generated endogenously, as well
as promoted exogenously by multiple environmental factors.
Ultraviolet irradiation (UV) is an environmental promoter
of oxidative stress. UV is known to damage DNA and other
intracellular proteins through direct and indirect mecha-
nisms. UV exists in three forms UVA (400–320nm), UVB
(320–290nm), and UVC (290–100nm). UVA and UVB are
the most biologically signiﬁcant, with UVC being most
absorbed by ozone [29]. UV is known to directly induce the
cross-linkingofneighboringpyrimidinestoformpyrimidine
dimers in DNA that result in mutagenic DNA lesions [30–
35]. However, UV is known to promote ROS generation that
can damage a large number of intracellular proteins and can
indirectly damage DNA.
Associated with oxidative damage is lipid peroxidation.
High levels of ROS are detrimental and can cause damage to
variousbiomolecules,whichincludethefattyacidsidechains
of membrane lipids that form reactive organic products such
as malondialdehyde and 4-hydroxynonenal, both of which
can generate DNA adducts and point mutations [36]. Lipid
peroxidation not only aﬀects DNA stability, but can also alter
lipid membrane proteins that are involved in signal trans-
duction pathways to promote constitutive activation and
downstream cellular proliferation. Furthermore, previous
studieshaveshownthatproductsoflipidperoxidationserved
as intermediates in the activation of signaling pathways that
involved phospholipase A2 and the MAPK pathway, both
associated with UV-induced carcinogenesis [37–39].
Although there are various sources of endogenous oxida-
tive stress, mitochondria are the major cellular organelles
that contribute to intracellular ROS generation. Mitochon-
dria consume approximately 80–90% of the cell’s oxygen for
ATP synthesis via oxidative phosphorylation. In the early
1920s Otto Warburg and colleagues theorized that defective
oxidative phosphorylation during cancer progression caused
tumor cells to undergo a metabolic shift requiring high rates
of glycolysis that promoted lactate production in the pres-
ence of oxygen. This phenomenon became known as aerobic
glycolysisandlatercoined“TheWarburgEﬀect.”Someofthe
metabolicenzymesthatarealteredduringcancerprogression
are involved in the mitochondrial electron transport chain
[40, 41]. The electron transport chain consists of a constant
ﬂow of electrons through mitochondrial intermembrane
complexeswithmolecularoxygenbeingtheultimateelectron
acceptor. The process of the electron transport chain is used
to pump protons into the mitochondrial inner membrane
creatinganelectrochemicalgradient.Thegradientthatiscre-
ated is coupled to ATP synthesis. However, leaking electrons
contribute to the incomplete reduction of molecular oxygen,
resulting in superoxide anion formation. Mitochondria are
readily susceptible to oxidative damage for various reasons:
( 1 )l a c ko fe ﬀective base excision repair mechanisms; (2) the
close proximity of mitochondrial DNA to ROS generation;
(3) lack of mitochondrial DNA protective histones [42].
Therefore, alterations in mitochondrial ROS generation
and protection via antioxidant expression are key in the
detrimental eﬀects of disease progression.
3. Manganese SuperoxideDismutase(MnSOD)
Maintainingabalancebetweenfreeradicalsandantioxidants
is required for cellular homeostasis. However, when thisJournal of Signal Transduction 3
balance is altered in favor of free radical generation, normal
physiology is altered and the pathogenesis of disease is
promoted. Antioxidants are endogenous defense mecha-
nisms utilized by the cell to ﬁght against ﬂuctuations in
free radical generation, which include both enzymatic and
nonenzymatic contributors. Ascorbic acid (Vitamin C) and
α-tocopherol (Vitamin E) are nonenzymatic antioxidants
that have been previously shown to eﬀectively scavenge free
radicals. On the other hand, antioxidants such as glutathione
peroxidase and superoxide dismutase are enzymatic antiox-
idants that catalyze the neutralization of free radicals into
products that are nontoxic to the cell. Superoxide dismutase
catalyzes the dismutation of superoxide anions leading to
the formation of hydrogen peroxide and molecular oxygen.
Hydrogen peroxide is further detoxiﬁed to water via catalase
and other endogenous antioxidant enzymes. The superoxide
dismutase family consists of metalloenzymes. Currently,
there are three major superoxide dismutase enzymes within
the human cell:manganesesuperoxide dismutase (MnSOD),
copper-zinc superoxide dismutase (Cu, ZnSOD), and extra-
cellularsuperoxidedismutase(ECSOD).MnSODislocalized
in the mitochondrial matrix [43], Cu, ZnSOD is found
primarily in the cytosol [44] and can be detected in the mi-
tochondrial intermembrane space [45], and ECSOD is a
homotetrameric glycosylated form of Cu, ZnSOD found in
the extracellular space [46].
MnSOD is ubiquitously found in both prokaryotes and
eukaryotes, and its increased activity is often associated with
cytoprotection against oxidants. MnSOD can be induced by
various mediators of oxidative stress such as tumor necro-
sis factor, lipopolysaccharide, and interleukin-1 [47]. This
antioxidant enzyme is nuclear encoded by a gene localized
to chromosome 6q25 [48], a region often lost in cancers
suchas melanoma [49]. MnSODis synthesized in the cytosol
as a larger precursor with a transit peptide on the N-
terminus and imported to the mitochondrial matrix via
proteolytic processing to the mature form [50]. Most cancer
cells and in vitro transformed cell lines have diminished
MnSOD activity compared to normal counterparts [51]. In
addition,deﬁcienciesinMnSODmaycontributetooxidative
stress generation that promotes neoplastic transformation
and/or maintenance of the malignant phenotype. In looking
at the correlation between MnSOD expression and cancer
progression, mutations within the MnSOD gene and its
regulatory sequence have been observed in several types of
human cancers [52, 53]. However, antioxidants can suppress
carcinogenesis, particularly during the promotion phase.
In addition, our laboratory as well as others has shown
that overexpression of MnSOD reduces tumor multiplicity,
incidence, and metastatic ability in various in vitro and in
vivo models [54–57].
4. The Tumor Suppressor p53
p53 is a well-characterized transcription factor known to
induce its tumor suppressor activity by activating genes
known to play a role in cell cycle arrest, such as p21CIP1
and GADD45. These genes, once activated, arrest the cell
c y c l et oa l l o wf o ra d e q u a t eD N Ar e p a i rt or e s t o r en o r m a l
cell proliferation. However, if the cell becomes overwhelmed
by the stressor or the DNA damage cannot be repaired, p53
can ultimately induce apoptosis. The tumor suppressive
activities of p53 can also be deﬁned by the induction senes-
cence. Senescence is characterized by irreversible loss of pro-
liferative potential, acquisition of characteristic morphology,
and expression of speciﬁc biomarkers such as senescence-
associated β-galactosidase [58]. Nevertheless, how p53 reg-
ulates senescence is often contradictory and dependent on
ROS generation. p53 can mediate cellular senescence via the
transactivation of p21CIP1. Nonetheless, emerging evidence
suggests ROS as a common mediator of senescence with
the involvement of superoxide dismutase and p53. Blander
et al. reported that RNAi-mediated knockdown of SOD1 in
primary human ﬁbroblasts induced cellular senescence me-
diated by p53. However, senescence was not induced in
p53-deﬁcient human ﬁbroblasts [59]. Furthermore overex-
pression of MnSOD induced growth arrest in the human
colorectal cancer cell line HCT116 and increased senescence
which required the induction of p53 [60]. On the contrary,
p53 can suppress senescence through the inhibition of the
mTOR pathway via multiple mechanisms [61–63]. Never-
theless, this diverse biological spectrum of p53 regulation of
cellular function remains complex and is dependent on the
source of activation and cell type.
There are various sources of p53 activators, which
include nucleotide depletion, hypoxia, ultraviolet radiation,
ionizing radiation, as well as many chemotherapeutic drugs
can act as activators of p53 (i.e., Doxorubicin). In normal
cells, p53 remains at a low level and is under strict control
by its negative regulator Mdm2. p53 induces autoregulation
via Mdm2. As a transcription factor, p53 can bind to the
promoter region of the mdm2 gene to promote transcription
of Mdm2 mRNA [64, 65]. Following proper translation into
a functional protein, Mdm2 acts as an E3 ligase during
p53 activation. Mdm2 can polyubiquitinate p53 leading to
proteasomal degradation [66]. However, Mdm2 can also
monoubiquinate p53 leading to intracellular traﬃcking [67].
T h ed e c i s i v er o l eo fp 5 3t oi n d u c ec e l lc y c l ea r r e s t ,s e -
nescence, or apoptosis involves intricate posttranslational,
as well as, transcription-dependent and transcription-inde-
pendent mechanisms. The tumor suppressor p53 is a well-
characterizedtranscriptionfactorknowntoinducethetrans-
activation of proapoptotic genes such as Bax, Puma, Noxa,
Bid and represses the transcription of anti-apoptotic genes
such as Bcl-2, Bcl-xL, and survivin [68, 69]. Nevertheless,
p53 can induce apoptosis independent of its transcriptional
activity. Manyof the transcription-independent mechanisms
of p53 were discovered through the use of inhibitors of
transcription/translation, as well as p53 truncated mutants
with altered subcellular localization, DNA binding, and co-
factor recruitment. The p53 monomer consists of various
multifunctional domains including the N-terminal trans-
activation domain (residues 1–73), a proline-rich region
(residues 63–97), the highly conserved DNA-binding core
domain (residues 94–312), a tetramerization domain located
within the C-terminus (residues 324–355), and an unstruc-
turedbasicdomain(residues360–393)[70](Figure 1).There
are multiple polymorphisms that occur within the TP34 Journal of Signal Transduction
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Figure 1:p53Multifunctionaldomains.Thep53monomerconsists
ofvariousmultifunctionaldomainsincludingtheN-terminaltrans-
activation domain (residues 1–73), a proline-rich region (residues
63–97), the highly conserved DNA-binding core domain (residues
94–312), a tetramerization domain located within the C-terminus
(residues 324–355), and an unstructured basic domain (residues
360–393).
gene that may enhance or alter p53 functionality. Dumont
et al. discovered functional diﬀerences in polymorphic
variants that enhanced p53-mediated apoptosis independent
of its transactivation abilities [71]. A common sequence
polymorphism that occurs within the proline-rich domain
encoding arginine at position 72 exhibited a ﬁvefold increase
in inducing apoptosis compared to the common proline
(Pro72) variant. These results suggested two mechanisms of
Arg 72 apoptotic enhancement: (1) increased mitochondrial
localization; (2) enhanced binding of the Arg 72 variant
to the negative p53 regulator E3 ligase, Mdm2. Although
increased binding to Mdm2 did not augment p53 degrada-
tion, it was suggested that the altered conﬁrmation of the
p53 Arg 72 variant enhanced the binding ability and facili-
tated greater nuclear export [71]. This suggests the impor-
tance of understanding the regulation of structure-activity
relationships in polymorphic forms of p53 in transcription-
independent apoptosis.
During p53-mediated apoptosis, a distinct cytoplasmic
pool of p53 translocates to the mitochondria. To promote
mitochondrial translocation, the E3 ligase, Mdm2 monou-
biquitinates p53 [72]. Since the p53 protein lacks a mito-
chondrial localization sequence, p53 interacts with Bcl-2
family proteins via Bcl-2 homology (BH) domains. The
presence of the BH domain allows proteins to regulate and
interact with other Bcl-2 members that consist of multiple
BH domains [73]. Once p53 arrives at the mitochondrial
outer membrane, p53 binds to Bak inducing a conforma-
tional change and Bak homo-oligomerization that results in
mitochondrial outer membrane permeabilization (MOMP).
MOMPallowsforthereleaseofpro-apoptoticsignalingmol-
ecules from the outer and inner mitochondrial membranes
into the cytosol triggering the intrinsic apoptotic signaling
cascade. ROS generation has been suggested as an alternative
p53 apoptotic target independent of cytochrome c release. Li
etal.foundthatROSgenerationregulatedthemitochondrial
membrane potential (Δψ), which was found to be a key
constituent in the induction of p53-mediated apoptosis [74].
Interestingly, during ROS generation, apoptosis occurred
in the absence of Bax mitochondrial translocation, Bid
a c t i v a t i o n ,a sw e l la sc y t o c h r o m ec release. Several studies
have suggested that the downstream eﬀects of p53-mediated
apoptosis are regulated by Bax expression. It has been
shown that the introduction of recombinant Bax protein
into isolated mitochondria induced cytochrome c release.
The ability of Bax to initiate pore formation in synthetic
membranes has been shown to regulate cytochrome c release
resulting in the induction of apoptosis [75, 76]. However,
discrepancies exist with in vivo studies showing Bax being
localizedinthecytosol,ratherthanwithinthemitochondrial
membrane at physiological conditions [77].
Herein, we show how p53 has been shown to play
a dual role in early-versus late-stage cancer progression.
During the process of carcinogenesis, mutations can occur
both upstream and downstream of p53 activation. For ex-
ample, loss of upstream activators of p53, for example,
ATM and Chk2, can prevent p53 activation, contributing
to unregulated cell cycling and promoting tumorigenesis
[78]. In addition, mutations within the p53 protein can
alter necessary structure conformational changes and DNA
binding properties needed for eﬃcient p53 activation. Lastly,
many of these mutations lead to loss of downstream genes
such as Bax or NOXA which are pro-apoptotic and necessary
for regulation of cellular proliferation and death signaling.
The process of tumor formation is a multistage process
that involves both the activation of protooncogenes, and the
inactivation of tumor suppressor genes, such as PTEN and
p53. The multistage carcinogenesis paradigm consists of
three well-characterized stages: initiation, promotion, and
progression. During the initiation stage, there is the induc-
tionofmutationswithincriticaltargetgenesofstemcells,for
example, H-ras; however in the skin carcinogenesis model,
the epidermal layer remains phenotypically normal. During
the tumor promotion stage, a noncarcinogenic agent such as
a phorbol ester can be used to induce the clonal expansion
of the initiated stem cells through epigenetic mechanisms.
This stage is often used by investigators to identify potential
therapeutic targets due to its reversibility. During the tumor
progression stage, malignancy takes place, being character-
ized by enhanced invasiveness via the activation of proteases,
and metastasizes via tumor cells entering into the lymphatics
and loss of tumor suppressor activity (e.g., p53).
Thetwo-stageskincarcinogenesismousemodelhasbeen
well characterized and used in numerous studies to screen
anti cancer agents. An initiator, such as dimethylbenz[a]an-
thracene (DMBA), is applied to the skin to initiate DNA
damage within skin cells. Following DMBA treatment, a
tumorpromotersuchas12-O-tetradecanoylphorbol-13-ace-
tate (TPA) is applied topically to the same area repeatedly for
the duration of the study to promote the clonal expansion
of mutated cells during the promotion stage. Interestingly,
during the early stages of DMBA/TPA-mediated tumor pro-
motion both oncogenes and tumor suppressor genes are ac-
tivated, resulting in increased cell proliferation being accom-
paniedbyincreasedcelldeath[79](Figure 2).Bothprocesses
existthroughoutskintumorformation.Notsurprising,these
two opposing events are closely related.
Many of the tumor-promoting mechanisms utilized by
phorbol esters are directly linked to the involvement of cell
surface membranes [80, 81]. TPA can mediate its pleiotropicJournal of Signal Transduction 5
Carcinogens
Tumor formation
Tumor suppressor
gene activation
Oncogene
activation
stress
p53 activation Ras-Rac1-NADPH oxidase
pathway
Apoptosis
reduced MnSOD activity
Oxidative
Carcinogens
Figure 2: Mechanisms of carcinogens in early stage carcinogenesis. During the early stages of tumor promotion both oncogenes and tumor
suppressor genes are activated, resulting in increased cell proliferation being accompanied by increased cell death.
actionsthroughintercalatingintothecellularmembraneand
inducing the activation of the Ca2+-activated phospholipid-
dependent protein kinase, protein kinase C (PKC) both in
vitroandinvivo.TPAcandirectlyactivatePKCviamolecular
mimicry by substituting for diacylglycerol, the endogenous
substrate, increasing the aﬃnity of PKC for Ca2+ which
leads to the activation of numerous downstream signaling
pathways involved in a variety of cellular functions including
proliferation and neoplastic transformation [82]. In addi-
tion, it is known that a direct correlation exists between
phorbol ester-mediated tumor promotion and enzymatic
activation of PKC [82, 83]. The PKC family consists of var-
ious highly conserved serine/threonine kinases. PKCs are
involved in numerous cellular processes including cell dif-
ferentiation, tumorigenesis, cell death, aging, and neurode-
generation [84]; however the induction of the signaling
pathway is determined by the intracellular redox status and
the isoform that is activated. The PKC family consists of a
myriad of isoforms that have been divided into three classes:
(a) classical or conventional PKCs (cPKC: α, βI, βII, and γ);
(b) novel PKCs (nPKC: δ, ε, η,a n dθ); (c) the atypical PKCs
(aPKC: λ, ι,a n dζ) which are classiﬁed based on sensitivity
to Ca2+ and diacylglycerol (DAG) [84]. In various types of
cancers PKCε has been shown to be upregulated while PKCα
and PKCδ are downregulated. Interestingly, TPA activates
the PKCε isoform in mouse skin tissues [85]. Furthermore,
overexpression of PKCε has been shown to enhance the
formationofskincarcinomas[86].Moreover,TPAtreatment
leads to the concomitant activation of the redox-sensitive
transcription factor activator protein-1 (AP-1) [85]. The
AP-1 complex consists of both Jun and Fos oncoproteins.
There are 3 jun isoforms (c-jun, jun-B, and jun-D) and 4 fos
family members (c-fos, fra-1, fra-2, and fos-B) [87] whose
activation is modulated by oxidants such as superoxide and
hydrogen peroxide, while DNA binding activities are mod-
ulated by the intracellular redox status [88–90]. Kiningham
and Clair reported a reduction in tumorigenicity and AP-1
DNAbindingactivityfollowingoverexpressionofMnSODin
transfected ﬁbrosarcoma cells [91]. Furthermore, the protein
expression of Bcl-xl, an antiapoptotic AP-1 target gene, was
decreased, as well. In addition, PKCε activation was reduced
in MnSOD transgenic mice treated with DMBA/TPA com-
pared to their nontransgenic counterparts [85]. These results
suggest a mechanistic linkage between MnSOD expression,
mitogenic activation, and AP-1 binding activity.
5. MnSOD-p53 Mitochondrial Interaction
Another activated signaling pathway that has been deﬁned
following DMBA/TPA treatment is the Ras-Rac1-NADPH
oxidase pathway, which leads to p53 mitochondrial translo-
cation and apoptosis [92]. NADPH oxidase forms a stable
heterodimer with the membrane protein p22phox,w h i c h
serves as a docking site for the SH3 domain-containing
regulatory proteins p47phox,p 6 7 phox,a n dp 4 0 phox.U p o nT P A
treatment, Rac, a small GTPase, binds to p67phox which
induces NADPH oxidase activation [11]a n ds u p e r o x i d e
production. Mitochondrial p53 has been shown to interact
with MnSOD, resulting in decreased enzymatic activity and
promoting oxidative stress propagation [93].
The primary role of MnSOD is to protect mitochondria
from oxidative damage. In 2005, Zhao et al. found that
TPA treatment, both in vitro and in vivo, can induce p53
mitochondrial translocation [93]. In addition, p53 not only
came in contact with the outer mitochondrial membrane
but was able to localize to the mitochondrial matrix.
Interestingly, following p53 mitochondrial translocation and6 Journal of Signal Transduction
matrix localization, p53 interacted with the mitochondrial
antioxidant enzyme MnSOD that resulted in a reduction in
MnSOD activity and propagation of oxidative stress [93].
However, the question remains: does mitochondrial p53
contribute to or suppress tumor promotion during the early
stages of skin carcinogenesis? We addressed this question by
utilizing the JB6 mouse skin epidermal cells. JB6 cells were
originally derived from primary BALB/c mouse epidermal
cell culture [94]. Through nonselective cloning, it was dis-
coveredthatclonalvariantsexistedwithintheJB6celllineage
that were either stably sensitive (P+) or resistant (P−)t ot u -
mor promoter-induced neoplastic transformation [95–97].
In addition, JB6 cells remain the only well-characterized skin
keratinocytes for studying tumor promotion and screening
anti-cancer agents. In 2010, we utilized the JB6 P+ and P−
clonal variants to determine if a relationship existed be-
tween tumor promotion and early-stage TPA-induced p53
activation [98]. Surprisingly, we found that p53 was only
induced in promotion-sensitive P+ cells and not promotion
resistant (P−) cells, therefore suggesting that p53 expression
is highly associated with early stage tumor promotion. We
then assessed Bax protein expression levels, as a marker for
p53 transcriptional activity, and found that Bax expression is
only induced in JB6 P+ cells and not P− cells,suggesting that
p53expression,aswellastranscriptionalactivity,ishighlyas-
sociated with early-stage tumor promotion following TPA
treatment. MnSOD expression was also measured in both
JB6 P+ and P− cells and was found to be highly expressed
in promotion-resistant P− cells compared to promotable P+
cells.TPA-mediatedROSgenerationwasmeasuredinP+and
P− cells (unpublished data), and promotion resistant cells
contained signiﬁcantly lower levels of ROS following TPA
treatment when compared to their promotable counterparts.
It is known that reduced MnSOD expression contributes to
increased DNA damage, cancer incidence, and radical-
caused diseases [99, 100]. Consistent with that, an increase
of several markers of oxidative damage such as 4-HNE, 8-
oxoDG, and lipid peroxidation has been seen in both in vitro
and in vivo studies following TPA treatment [57, 85, 101,
102], suggesting the involvement of oxidative stress in the
promotion of tumorigenesis. These results imply the impor-
tance of redox regulation in modulating cellular functions
during the early stage of tumor promotion. We questioned
whether the ROS generated from the MnSOD-p53 mito-
chondrial interaction was suﬃcient to promote tumorigen-
icity. Therefore, we utilized promotion-resistant JB6 P− cells
that exhibited no p53 protein expression or transactivation
following TPA treatment to address this question. Inter-
estingly, we found that when JB6 promotion-resistant cells
were transfected with wild-type p53, these cells were able
to transform and form colonies in soft agar, in comparison
to their control counterparts [98]. These results suggest a
dual role of p53-mediated ROS generation during the early
stages of skin carcinogenesis and how the presence of p53 is
necessary for tumor promotion in skin (Figure 3).
The contradictory role of p53 in promoting cell survival
or death is the result of the ability to regulate the expression
of both pro- and antioxidant genes. For example, p53 can
promote the generation of ROS through the induction of
genes involved in mitochondrial injury and cell death
which include Bax, Puma, and p66SHC and ROS-generating
enzymes such as quinine oxidoreductase (NQO1) and pro-
line oxidase [103]. However, p53 can upregulate the expres-
sion of various antioxidant enzymes to modulate ROS levels
and promote cell survival such as aldehyde dehydrogenase 4
and mammalian sestrin homologues that encode peroxire-
doxins and GPX1, which are major enzymatic removers of
peroxide [103].
Dhar et al. suggested that p53 possessed “bidirectional”
regulation of the antioxidant MnSOD gene. Previous reports
suggest the presence of a p53 binding region at 328bp and
2032bp upstream of the transcriptional start site of the
MnSOD gene [104, 105]. Others suggest that p53 represses
MnSOD gene expression by interfering with transcription
initiation [106], inhibiting gene activators at the promoter
level by forming an inhibitory complex suppressing gene
transcription [107] and protein-protein interactions [108].
Nevertheless, p53 can induce the gene expression of MnSOD
[104]. p53-mediated MnSOD expression is regulated in
conjunctionwithothercellproliferativetranscriptionfactors
such as NF-κB. Kiningham and Clair demonstrated the
presence of an NF-κB binding site within the intronic
enhancer element of the MnSOD gene [91]. It was later
shown that mutation of the NF-κB site within the enhancer
element abrogated p53 induced MnSOD gene transcription.
In addition, knockdown of p65 via siRNA reduced MnSOD
gene transcription via p53 as well. Overall the eﬀects of
p53 on MnSOD gene expression have been suggested to
be concentration dependent, with low concentrations of
p53 increasing MnSOD expression via corroborative NF-
κB binding promoting cell survival and high concentrations
of p53 suppressing MnSOD expression by interfering with
important transcriptional binding elements such as SP1.
6. ClinicalImplicationsof the
MnSOD-p53 Interaction
p53 is mutated in 50% of human cancers. However, the
remaininghumantumorscontainwild-typep53withdefects
in the downstream mediated p53-signaling pathways. This,
in turn, provides novel areas of discovery in stabilization
and restoration of wild-type p53 activity. Currently, many
drug companies are focused on utilizing p53 interactions as
targets for pharmacological intervention [78]. There are var-
ious protein-protein interactions that occur within the cell
that positively or negatively regulate p53 expression and
function. For example, Mdm2 is an E3 ligase of p53 that
polyubiquitinates p53, priming the tumor suppressor for
proteasomaldegradation.Manyhavefoundthat,byblocking
this interaction through peptides or transcriptional inhibi-
tors, longer durations of p53 activation have resulted. Some
of the therapeutic strategies that are currently being utilized
are peptides that increase p53 activation through inhibition
of Mdm2 function [109]. Three-dimensional structural
models [110] of the hdm2-p53 interaction along with bi-
ochemical data [111, 112] have identiﬁed three residues that
are important to this interaction, Phe19, Trp23, and Leu26Journal of Signal Transduction 7
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Figure 3:Mechanism involvingthep53-MnSODinteraction duringtheearly stageof tumorpromotion.Following exposuretoacarcinogen
the Ras-Rac1-NADPH oxidase pathway is activated, which leads to p53 mitochondrial translocation. Mitochondrial p53 has been shown to
interact with MnSOD, resulting in decreased enzymatic activity and promoting oxidative stress propagation contributing to the early stage
of skin tumorigenicity. Elevated levels of MnSOD reduced oxidative stress propagation, suppressed p53 mitochondrial translocation, and
decreased downstream skin tumor formation. Reduced levels of MnSOD have been shown to contribute to oxidative stress propagation and
promote early-stage skin tumorigenicity.
[111, 112]. From this data, an 8-mer peptide was generated
[113] and showed promising results in inducing apopto-
sis in tumor cells that overexpressed hdm2 [112]. How-
ever, these conditions were diﬃcult to optimize with a
smaller molecule therefore causing this peptide to be ther-
apeutically ineﬃcient. Also nutlins have been utilized to dis-
rupt the mdm2-p53 interaction resulting in reactivation of
the p53 response [114, 115]. Others have used antisense and
transcription inhibitors to prevent the expression of Mdm2
[116].
Gene replacement therapy is another therapeutic modal-
ity that has been explored in treating tumors lacking or
containingmutantp53.Thistechniqueutilizesadenoviruses,
as well as retroviruses to achieve high expression of p53 in
tumor cells. Promising results have been seen with retroviral
vectors in patients with nonsmall cell lung cancers [117]. On
the contrary, although we have seen the enhancement of
tumorigenicity in our in vitro p53 transfection studies [98],
we have not tested stably transfected cells in in vivo xenograft
mouse models, nor have we tried other tissue types. There-
fore, the reintroduction of the p53 gene into tumors may
have contradictory outcomes depending on the cell type and
tissue microenvironment. This concern has echoed through
various studies, persuading investigators to opt to combine
gene therapy with chemotherapy and radiotherapy [118–
121].
For decades, it has been shown that p53 functions only
as a tumor suppressor. In addition, p53-mediated ROS
generation has been limited to the induction of apoptosis.
Currently, the ability of wild-type p53 to contribute to tu-
mor promotion has received considerable attention. We have
shown that the p53-MnSOD interaction contributes to the
early stage of tumor promotion. In addition, it has been
consistently shown that MnSOD activity is altered in human
tumors. Therefore, designing diagnostic tools to assess
MnSOD activity, as well as p53 activation, can be used to
eﬀectively design individualized treatments for cancer pa-
tients. For example, following chemotherapeutic treatment,
patients that have higher levels of p53 expression and exhibit
lower levels of MnSOD can receive an SOD mimetic that can
upregulate MnSOD or synthetic compounds that can down-
regulate p53 activity to decrease ROS-mediated apoptosis
and potential relapse within these patients.
Gene therapy has also been utilized to modulate MnSOD
activity during cancer progression. Overexpression of
MnSOD through gene therapy introducing genetically
engineered DNA/liposomes containing the human MnSOD
transgene into preclinical and clinical models has been
shown to be protective in normal tissues against ionizing
irradiation. The ﬁnal product (VLTS-582) is a DNA/lipo-
some formulation that consists of a double-stranded DNA
bacterial plasmid containing human MnSOD cDNA in con-
junction with two lipids {cholesterol and DOTIM (1-[2-
[9-(2)-octadecenoyloxy]]-2-[8-(2)-heptadecenyl]-3-[hydrox-
yethyl] imidazolinium chloride)} [122]. Recent studies
suggest that this formulation has been successful in murine8 Journal of Signal Transduction
models and has been administered orally to patients concur-
rently with a weekly chemotherapy regime exhibiting no
dose-limiting toxicities. Although proven therapeutically
efﬁcacious, more studies are needed to improve (1) delivery
of the transgene to the targeted tissue; (2) reducing rapid
elimination of the transgene; (3) control of the expression of
the transgene within targeted tissues.
On the other hand, a topical application of an SOD
mimetic has also been described [123]. The Mn (III)
porphyrin MnIII TE-2-Pyp5+ possesses highly potent SOD
activity as facilitated by the redox properties of the metal
center and the positive charge to the ortho-N-ethylpyridyl
nitrogens [124]. MnIII TE-2-Pyp5+ has been proven eﬀective
in vitro and in various human diseases such as stroke [125,
126], diabetes [127, 128], and cancer and radiation-related
treatment [129–132]. In preclinical animal models, topical
application of MnIII TE-2-Pyp5+ was shown to reduce levels
of oxidative damage and reduced cell proliferation without
interfering with p53-mediated apoptosis when applied prior
to TPA treatment [129]. These data support the concept that
overexpressionofMnSODwhenappliedinconjunctionwith
standard chemotherapeutics or during the tumor promotion
stage is protective in both preclinical and clinical models.
Nevertheless, both p53 and MnSOD have been shown
to posses reduced activity and/or mutated in most human
diseasesincludingcancer.Therefore,moretherapeuticquests
are needed to detect and restore both MnSOD and wild-
type p53 activity. However, future therapeutic optimization
strategies should have minimal nonspeciﬁc drug-related tox-
icities and be based on the stage of cancer progression which
may reveal a therapeutic window for treatment intervention.
7. Concluding Remarks
In summary, reactive oxygen species have been implicated in
the pathogenesis of various hyperproliferative and inﬂam-
matory diseases [133]. In addition, the tumor suppressor
p53 has been shown to be activated during the early stage
of skin carcinogenesis and contributed to the propagation
of oxidative stress. Recent studies demonstrate a novel role
of mitochondrial p53 activation. Once in the mitochondria,
p53 physically interacts with MnSOD. As a result, this in-
teraction reduces the free radical scavenging abilities of
MnSOD, promoting enhanced ROS generation which has
been shown to act as a tumorigenic stimulus during cancer
progression. This suggests that wild-type p53 may play a
direct role in promoting oxidative stress and contributing to
the ROS-mediated tumor-proliferative stimuli. In addition,
others have shown that mutant p53 can, in fact, translocate
to the mitochondria and interact with MnSOD [134]. How-
ever, Lontz et al. observed following doxorubicin treatment
of lymphoma cell lines with varying wt or mutant p53
levels, mitochondrial function, as evidenced by Complex
I/II activities, was only compromised in lymphoma cells
expressing wild-type and not mutant p53 [134]. Therefore,
the continuation of deciphering mechanistic diﬀerences in
tumors containing wild-type or mutant p53 can lead to the
development of therapeutic p53-mediated interventions and
aclearerunderstandingofchemoresistanceinbothwild-type
and mutant p53 human tumors.
Several studies have suggested that MnSOD may play a
primary protective role against tissue injury. MnSOD has
been found to be depleted in a variety of tumor cells,
as well as in vitro transformed cell lines, suggesting that
MnSODmayactasanoveltumorsuppressor,protectingcells
from oxidant-induced carcinogenesis [135]. Nevertheless,
overexpression of MnSOD decreases the pathogenesis of
human diseases such as cancer. Consistent with that, accu-
mulating evidence suggests that a number of antioxidants
or drugs with antioxidant properties can reduce mediators
of tumor promotion [136]. Clair et al. showed that trans-
fecting mouse 10T 1/2 cells with human MnSOD cDNA
promoted diﬀerentiation with 5-azacytidine treatment and
protected against neoplastic transformation [137]. In addi-
tion, transfecting human MnSOD cDNA into MCF-7 breast
cancer cells and UACC-903melanoma cells suppressed their
malignant phenotype and suppressed growth in nude mice
[54, 138]. We have shown that the cumulative induction of
endogenous antioxidant enzymes (i.e., catalase, total SOD
and MnSOD) is eﬃcient in reducing tumor incidence and
multiplicity [57]. In addition, the induction of endogenous
antioxidant enzymes via dietary administration can suppress
p53 mitochondrial translocation [98]. TPA can induce p53
mitochondrialtranslocation;however,thisphorbolesteralso
decreases the mitochondrial membrane potential, as well
as mitochondrial complex activities and respiration. Other
studies have shown that MnSOD overexpression in mice
protects complex I from adriamycin-induced deactivation in
cardiac tissue [139]. These results suggest that antioxidant
expression protects against ﬂuctuations in mitochondrial
functions which suppress p53 mitochondrial translocation,
p53-mediated ROS, and both downstream apoptotic and cell
proliferation signaling pathways. On the contrary, Connor
et al. suggest that overexpression of MnSOD in HT-1080
ﬁbrosarcomacellsand253Jbladdertumorcellsenhancedthe
migatory ability and invasiveness of tumor cells, through the
upregulation of matrix metalloproteinases [140]. Although
some tumors express higher levels of MnSOD, the down-
stream eﬀects of enhanced antioxidant expression are depen-
dent on the tumor type and susceptibility to oxidative dam-
age, underlying oncogenic mutations and the stage of disease
progression [140]. Nevertheless, these investigators stressed
theneedofreﬁnedregulationofH2O2 production.Therefore
the question remains, are the eﬀects of the p53-MnSOD
interaction protumorigenic or anti-tumorigenic? To deﬁni-
tively answer this question further investigation of this inter-
action is needed. However, there are several factors that must
be considered in determining the fate of the p53-MnSOD
interaction, which include the stage of disease progression
as well as tumor microenvironment. It has been shown that
p53 activation is required in tumor promotion and can
mediate ROSgeneration. However, theduration of enhanced
ROS generation, severity of oxidative damage, and the status
of the cellular antioxidant capacity can all contribute to
the proliferative/apoptotic switch that occurs during the
response to cellular stress. Overall, further studies are needed
to clearly assess the status of MnSOD during the variousJournal of Signal Transduction 9
stages of carcinogenesis to enhance the eﬃcacy of standard
treatment regimens currently being used.
Consistent with that, deﬁning the downstream eﬀects
of the p53-MnSOD complex formation can expand our
knowledge of the molecular mechanisms that contribute to
the early stage of tumorigenesis and how they may be altered
during cancer progression. With further knowledge, modu-
lators of MnSOD, p53 and their associated regulators can be
therapeutically useful in the treatment of cancer and various
stages of tumor progression.
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